How to buy Mesoblast shares
Own Mesoblast shares in just a few minutes.
Mesoblast Limited is a biotechnology business based in Australia. Mesoblast shares (MSB) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Mesoblast has a trailing 12-month revenue of around $32.2 million.
How to buy shares in Mesoblast
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Mesoblast. Find the share by name or ticker symbol: MSB. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Mesoblast reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $N/A, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Mesoblast. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Mesoblast share priceUse our graph to track the performance of MSB stocks over time.
Mesoblast shares at a glance
|52-week range||AUDA$1.02 - AUDA$5.43|
|50-day moving average||AUDA$4.7675|
|200-day moving average||AUDA$3.4468|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||AUDA$-0.182|
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Mesoblast stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Revenue TTM||$32.2 million|
|Gross profit TTM||$6.8 million|
|Return on assets TTM||-6.82%|
|Return on equity TTM||-15.13%|
|Market capitalisation||$2.9 billion|
TTM: trailing 12 months
Mesoblast share dividends
We're not expecting Mesoblast to pay a dividend over the next 12 months.
Mesoblast share price volatility
Over the last 12 months, Mesoblast's shares have ranged in value from as little as $1.02 up to $5.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Mesoblast's is 2.8367. This would suggest that Mesoblast's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Frequently asked questions
Ask an Expert